Deconvolution-based Dynamic Contrast-enhanced MR Imaging of Breast Tumors: Correlation of Tumor Blood Flow with Human Epidermal Growth Factor Receptor 2 Status and Clinicopathologic Findings—Preliminary Results

Smitha Makkat

Robert Luypaert

Tadeusz Stadnik

Claire Bourgain

Published Online:Nov 1 2008https://doi.org/10.1148/radiol.2492071147

Abstract

Purpose: To prospectively determine whether breast carcinomas possess characteristic values of tumor blood flow (TBF) that correlate with pathologic and molecular prognostic markers.

Materials and Methods: The institutional ethics committee approved this study. After informed consent was obtained, 57 women (age range, 31–80 years) with histologically proved breast cancer underwent routine magnetic resonance (MR) mammography, which included a whole-breast dynamic contrast material–enhanced (DCE) sequence. A second contrast material bolus was injected during dynamic single-section turbo field-echo imaging of the section where the lesion was maximally enhanced. The relative signal intensity changes were deconvolved in a pixelwise fashion to yield the TBF. Formalin-fixed paraffin-embedded tumor specimens on slides were evaluated for histologic size and grade, as well as for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) protein. In patients with a HER2 protein score of 2+ or 3+, HER2 gene status was assessed. For all prognostic parameters, the Mann-Whitney U test was used to compare median TBF in the HER2-positive group with that in the HER2-negative group.

Results: Significantly higher TBF was observed in tumors larger than 2 cm in diameter and in PR-negative and HER2 gene–amplified tumors (P < .05). In the HER2-positive and HER2-negative groups, ER-positive PR-positive tumors had a lower median TBF than did ER-negative PR-negative tumors, and the difference was significant in the HER2-positive group (P < .05).

Conclusion: Pixelwise deconvolution analysis of DCE MR data in patients with breast cancer can provide preoperative information regarding TBF. These results also support the hypothesis that there is increased TBF in HER2-positive tumors.

References

1 Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992; 3: 65–71. Medline, Google Scholar
2 Degani H, Chetrit-Dadiani M, Bogin L, Furman-Haran E. Magnetic resonance imaging of tumor vasculature. Thromb Haemost 2003;89:25–33. Crossref, Medline, Google Scholar
3 Kuhl CK, Mielcareck P, Klaschik S, et al. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 1999;211:101–110. Link, Google Scholar
4 Brix G, Kiessling F, Lucht R, et al. Microcirculation and microvasculature in breast tumors: pharmacokinetic analysis of dynamic MR image series. Magn Reson Med 2004;52:420–429. Crossref, Medline, Google Scholar
5 Buckley DL, Drew PJ, Mussurakis S, Monson JR, Horsman A. Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI. J Magn Reson Imaging 1997;7:461–464. Crossref, Medline, Google Scholar
6 Knopp MV, Weiss E, Sinn HP, et al. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 1999;10:260–266. Crossref, Medline, Google Scholar
7 Su MY, Cheung YC, Fruehauf JP, et al. Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. J Magn Reson Imaging 2003;18:467–477. Crossref, Medline, Google Scholar
8 Pollitt MJ, Hanby AM, Horgan K, Murphy CE, Jones PF, Speirs V. Angiogenesis in breast cancer: how should we measure this? [review]. Oncol Rep 2005;13:931–936. Google Scholar
9 Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998;16:462–469. Crossref, Medline, Google Scholar
10 Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986;232:1644–1646. Crossref, Medline, Google Scholar
11 Blackwell KL, Dewhirst MW, Liotcheva V, et al. HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. Clin Cancer Res 2004;10:4083–4088. Crossref, Medline, Google Scholar
12 Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH. Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 2005;97:172–187. Crossref, Medline, Google Scholar
13 Sourbron S, Dujardin M, Luypaert R, et al. Quantification of cerebral tumor perfusion and permeability with a deconvolution analysis of T1-weighted bolus tracking data [abstr]. In: Proceedings of the 12th Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 2004; 188. Google Scholar
14 Sourbron S, Dujardin M, Makkat S, Luypaert R. Pixel-by-pixel deconvolution of bolus-tracking data: optimization and implementation. Phys Med Biol 2007;52:429–447. Crossref, Medline, Google Scholar
15 Makkat S, Sourbron S, Dujardin M, Van Schuerbeek P, Luypaert R, Stadnik T. Deconvolution-based contrast enhanced MR imaging of breast tumors for perfusion quantification: a feasibility study [abstr]. In: Proceedings of the 13th Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 2005; 743. Google Scholar
16 Makkat S, Luypaert R, Sourbron S, Stadnik T, De Mey J. Quantification of perfusion and permeability in breast tumors with a deconvolution-based analysis of second bolus T1-DCE data. J Magn Reson Imaging 2007;25:1159–1167. Crossref, Medline, Google Scholar
17 Osanai T, Wakita T, Gomi N, Takenaka S, Kakimoto M, Sugihara K. Correlation among intratumoral blood flow in breast cancer, clinicopathological findings and Nottingham prognostic index. Jpn J Clin Oncol 2003;33:14–16. Crossref, Medline, Google Scholar
18 Makkat S, Sourbron S, Dewilde V, et al. Characterization of breast tumors with a model-independent analysis of bolus-tracking MRI [abstr]. In: Proceedings of the 14th Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 2006; 1797. Google Scholar
19 Köstler H, Ritter C, Lipp M, Beer M, Hahn D, Sandstede J. Prebolus quantitative MR heart perfusion imaging. Magn Reson Med 2004;52:296–299. Crossref, Medline, Google Scholar
20 Sourbron S, Luypaert R, Van Schuerbeek P, Dujardin M, Stadnik T, Osteaux M. Deconvolution of dynamic contrast-enhanced MRI data by linear inversion: choice of the regularization parameter. Magn Reson Med 2004;52:209–213. Crossref, Medline, Google Scholar
21 Dujardin M, Sourbron S, Luypaert R, Verbeelen D, Stadnik T. Quantification of renal perfusion and function on a voxel-by-voxel basis: a feasibility study. Magn Reson Med 2005;54:841–849. Crossref, Medline, Google Scholar
22 Gribbestad IS, Nilsen G, Fjøsne HE, Kvinnsland S, Haugen OA, Rinck PA. Comparative signal intensity measurements in dynamic gadolinium-enhanced MR mammography. J Magn Reson Imaging 1994;4:477–480. Crossref, Medline, Google Scholar
23 Tsuda H, Hirohashi S, Shimosato Y, et al. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma: a retrospective analysis of 176 cases. Cancer 1990;65:1794–1800. Crossref, Medline, Google Scholar
24 Bourgain C, Smitz J, Camus M, et al. Human endometrial maturation is markedly improved after luteal supplementation of gonadotrophin-releasing hormone analogue/human menopausal gonadotrophin stimulated cycles. Hum Reprod 1994;9:32–40. Google Scholar
25 Fisher ER, Anderson S, Dean S, et al. Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma. Cancer 2005;103:164–173. Crossref, Medline, Google Scholar
26 Bartlett JM, Going JJ, Mallon EA, et al. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 2001;195:422–428. Crossref, Medline, Google Scholar
27 McCormick SR, Lillemoe TJ, Beneke J, Schrauth J, Reinartz J. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. Am J Clin Pathol 2002;117:935–943. Crossref, Medline, Google Scholar
28 Nabavi DG, Cenic A, Craen RA, et al. CT assessment of cerebral perfusion: experimental validation and initial clinical experience. Radiology 1999;213:141–149. Link, Google Scholar
29 Craft PS, Harris AL. Clinical prognostic significance of tumour angiogenesis. Ann Oncol 1994;5:305–311. Crossref, Medline, Google Scholar
30 Mussurakis S, Buckley DL, Horsman A. Prediction of axillary lymph node status in invasive breast cancer with dynamic contrast-enhanced MR imaging. Radiology 1997;203:317–321. Link, Google Scholar
31 Teifke A, Behr O, Schmidt M, et al. Dynamic MR imaging of breast lesions: correlation with microvessel distribution pattern and histologic characteristics of prognosis. Radiology 2006;239:351–360. Link, Google Scholar
32 Tuncbilek N, Karakas HM, Okten OO. Dynamic magnetic resonance imaging in determining histopathological prognostic factors of invasive breast cancers. Eur J Radiol 2005;53:199–205. Crossref, Medline, Google Scholar
33 Stomper PC, Herman S, Klippenstein DL, et al. Suspect breast lesions: findings at dynamic gadolinium-enhanced MR imaging correlated with mammographic and pathologic features. Radiology 1995;197:387–395. Link, Google Scholar
34 Fischer U, Kopka L, Brinck U, Korabiowska M, Schauer A, Grabbe E. Prognostic value of contrast-enhanced MR mammography in patients with breast cancer. Eur Radiol 1997;7:1002–1005. Crossref, Medline, Google Scholar
35 Szabó BK, Aspelin P, Kristoffersen Wiberg M, Tot T, Boné B. Invasive breast cancer: correlation of dynamic MR features with prognostic factors. Eur Radiol 2003;13:2425–2435. Crossref, Medline, Google Scholar
36 Horak ER, Leek R, Klenk N, et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992;340:1120–1124. Crossref, Medline, Google Scholar
37 Choi WW, Lewis MM, Lawson D, et al. Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol 2005;18:143–152. Crossref, Medline, Google Scholar
38 Ludovini V, Sidoni A, Pistola L, et al. Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients. Breast Cancer Res Treat 2003;81:159–168. Crossref, Medline, Google Scholar
39 Ali SH, O'Donnell AL, Balu D, et al. Estrogen receptor-alpha in the inhibition of cancer growth and angiogenesis. Cancer Res 2000;60:7094–7098. Medline, Google Scholar
40 Konecny GE, Meng YG, Untch M, et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004;10:1706–1716. Crossref, Medline, Google Scholar
41 Kumar R, Yarmand-Bagheri R. The role of HER2 in angiogenesis. Semin Oncol 2001;28:27–32. Crossref, Medline, Google Scholar
42 Vogl G, Bartel H, Dietze O, Hauser-Kronberger C. HER2 is unlikely to be involved in directly regulating angiogenesis in human breast cancer. Appl Immunohistochem Mol Morphol 2006;14:138–145. Crossref, Medline, Google Scholar
43 Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997;151:1523–1530. Medline, Google Scholar
44 Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000;18:3651–3664. Crossref, Medline, Google Scholar
45 Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003;95:142–153. Crossref, Medline, Google Scholar
46 Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007;243:148–157. Link, Google Scholar
47 Knopp MV, Bourne MW, Sardanelli F, et al. Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine. AJR Am J Roentgenol 2003;181:663–676. Crossref, Medline, Google Scholar

Article History

Published in print: 2008

Vol. 249, No. 2

Metrics

Downloaded 397 times

Altmetric Score